Fig. 5: Specific T-cell responses measured by ELISpot before and after the booster vaccination. | Nature Communications

Fig. 5: Specific T-cell responses measured by ELISpot before and after the booster vaccination.

From: Effectiveness of a booster dose of aerosolized or intramuscular adenovirus type 5 vectored COVID-19 vaccine in adults: a multicenter, partially randomized, platform trial in China

Fig. 5

ELISpot responses for IFN-γ against wild-type SARS-CoV-2 (a) and BA.4/5 variant (b). ELISpot responses for IL-2 against wild-type SARS-CoV-2 (c) and BA.4/5 variant (d). Lines indicate the mean and error bars are 95% CIs. IM Ad5-nCoV against wild-type SARS-CoV-2: day 0 (n = 60), day 14 (n = 60), month 3 (n = 56), month 6 (n = 31); IH Ad5-nCoV against wild-type SARS-CoV-2: day 0 (n = 61), day 14 (n = 61), month 3 (n = 60), month 6 (n = 34). IM Ad5-nCoV against BA.4/5 variant: day 0 (n = 47), day 14 (n = 39), month 3 (n = 58), month 6 (n = 57); IH Ad5-nCoV against BA.4/5 variant: day 0 (n = 54), day 14 (n = 43), month 3 (n = 26), month 6 (n = 59). No technical replicates. The p values are the results of comparison between different time points using two-sided mixed-effects models (day 0 versus day 14 and month 3 versus month 6). The p values for multiple comparisons have been adjusted. IM Ad5-nCoV adenovirus type 5 vectored COVID-19 vaccine through intramuscular injection. IH Ad5-nCoV adenovirus type 5 vectored COVID-19 vaccine through oral inhalation, IFN interferon, IL interleukin, SFCs spot forming cells, PBMCs peripheral blood mononuclear cells.

Back to article page